Kathleen  Sebelius net worth and biography

Kathleen Sebelius Biography and Net Worth

Director of Humacyte

Ms. Sebelius is the Chair of the Humacyte Board of Directors. She is the Chief Executive Officer of Sebelius Resources LLC, which provides strategic advice to private companies, non-profit organizations, higher education institutions, and financial investors. In 2009, she was appointed Secretary of the U.S. Department of Health and Human Services (HHS) by President Barack Obama and served in that role until June 2014. Previously, Ms. Sebelius was the Governor of Kansas from 2003 to 2009, and before that, she served two terms as the Kansas Insurance Commissioner and four terms in the Kansas Legislature. Ms. Sebelius currently serves on the boards of directors of public companies Devoted Health, Inc., Include Health Inc., and Exact Sciences Corporation. She is a director of the Kaiser Family Foundation, co-chairs the Aspen Institute Health Strategy Group, and serves on advisory boards for the Dole Institute of Politics, Solera Health, Out Leadership, the Estée Lauder Foundation, the University of Kansas College of Liberal Arts and Sciences, and Zipline. Ms. Sebelius holds a Master of Public Administration degree from the University of Kansas and a B.A. from Trinity Washington University.

What is Kathleen Sebelius' net worth?

The estimated net worth of Kathleen Sebelius is at least $118.57 thousand as of April 8th, 2025. Ms. Sebelius owns 91,207 shares of Humacyte stock worth more than $118,569 as of December 5th. This net worth approximation does not reflect any other investments that Ms. Sebelius may own. Learn More about Kathleen Sebelius' net worth.

How do I contact Kathleen Sebelius?

The corporate mailing address for Ms. Sebelius and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected]. Learn More on Kathleen Sebelius' contact information.

Has Kathleen Sebelius been buying or selling shares of Humacyte?

Kathleen Sebelius has not been actively trading shares of Humacyte during the last quarter. Most recently, on Tuesday, April 8th, Kathleen Sebelius bought 50,000 shares of Humacyte stock. The stock was acquired at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares of the company's stock, valued at $120,393.24. Learn More on Kathleen Sebelius' trading history.

Who are Humacyte's active insiders?

Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), Laura Niklason (CEO), Shamik Parikh (Chief Medical Officer), Heather Prichard (COO), Dale Sander (CFO), William Scheessele (Chief Commercial Officer), and Kathleen Sebelius (Director). Learn More on Humacyte's active insiders.

Are insiders buying or selling shares of Humacyte?

During the last twelve months, Humacyte insiders bought shares 4 times. They purchased a total of 83,993 shares worth more than $118,224.22. During the last twelve months, insiders at the sold shares 6 times. They sold a total of 4,482,090 shares worth more than $7,466,382.20. The most recent insider tranaction occured on August, 20th when Director Brady W Dougan sold 591,685 shares worth more than $934,862.30. Insiders at Humacyte own 5.1% of the company. Learn More about insider trades at Humacyte.

Information on this page was last updated on 8/20/2025.

Kathleen Sebelius Insider Trading History at Humacyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2025Buy50,000$1.32$66,000.0091,207View SEC Filing Icon  
9/10/2024Sell5,182$5.40$27,982.8040,276View SEC Filing Icon  
See Full Table

Kathleen Sebelius Buying and Selling Activity at Humacyte

This chart shows Kathleen Sebelius's buying and selling at Humacyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Humacyte Company Overview

Humacyte logo
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $1.30
Low: $1.26
High: $1.33

50 Day Range

MA: $1.53
Low: $1.12
High: $2.48

2 Week Range

Now: $1.30
Low: $1.09
High: $6.77

Volume

3,077,595 shs

Average Volume

4,793,646 shs

Market Capitalization

$243.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9